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Background: MYST1 (also known as hMOF), a member of the MYST family of histone acetyltransferases (HATs) as
an epigenetic mark of active genes, is mainly responsible for histone H4K16 acetylation in the cells. Recent studies
have shown that the abnormal gene expression of hMOF is involved in certain primary cancers. Here we examined
the involvement of hMOF expression and histone H4K16 acetylation in primary renal cell carcinoma (RCC).
Simultaneously, we investigated the correlation between the expression of hMOF and clear cell RCC (ccRCC)
biomarker carbohydrase IX (CA9) in RCC.
Materials and methods: The frozen RCC tissues and RCC cell lines as materials, the reverse transcription
polymerase chain reaction (RT-PCR), western blotting and immunohistochemical staining approaches were used.
Results: RT-PCR results indicate that hMOF gene expression levels frequently downregulated in 90.5% of patients
(19/21) with RCC. The reduction of hMOF protein in both RCC tissues and RCC cell lines is tightly correlated with
acetylation of histone H4K16. In addition, overexpression of CA9 was detected in 100% of ccRCC patients (21/21).
However, transient transfection of hMOF in ccRCC 786–0 cells did not affect both the gene and protein expression
of CA9.
Conclusion: hMOF as an acetyltransferase of H4K16 might be involved in the pathogenesis of kidney cancer, and
this epigenetic changes might be a new CA9-independent RCC diagnostic maker.
Keywords: Renal cell carcinoma, hMOF, Carbonate anhydrase IXIntroduction
Changes of chromatin structure are mainly regulated by
epigenetic regulations including ATP-dependent remode-
ling of nucleosomes, the incorporation of variants histones
into nucleosomes and posttranslational modifications of
histones [1]. Post-translational modifications of the N-
terminal tails of histones include acetylation, methylation,
phosphorylation, ubiquitination, sumoylation, and ADP-
ribosylation [2,3]. Histone acetylation as one of the best
characterized epigenetic modifications is controlled by his-
tone acetyltransferases (HATs) and histone deacetylases
(HDAC). The balance between histone acetylation and* Correspondence: chunxi_wang@126.com; jjjin@jlu.edu.cn
†Equal contributors
1Urology Department, The First Clinical Hospital, Jilin University,
Changchun City, Jilin 130021, China
3College of Life Science, Jilin University, Changchun City, Jilin 130012, China
Full list of author information is available at the end of the article
© 2013 Wang et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the ordeacetylation serves as a key epigenetic mechanism for
gene expression, DNA repair, developmental processes
and tumorigenesis [4-6]. Thus, any reason to make this
imbalance can lead to abnormal cell function, even cancer.
MYST1 (also known as hMOF), is the human ortholog
of the Drosophila MOF protein containing chromodomain
and acetyl-CoA binding motif which is one of the key
components of the dosage compensation complex (DCC)
or the male specific lethal (dMSL) complex [7]. Recent
biochemical purifications revealed that hMOF forms at
least two distinct multi-protein complexes in mammalian
cells. One complex is the evolutionary conserved human
MSL complex which is responsible for the majority of his-
tone H4 acetylation at lysine 16 [8,9]. The other hMOF-
containing complex is the human non-specific lethal
(NSL) complex which is recently characterized by Cai Y
et al. [10]. hNSL complex can also acetylate histone H4 attd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the exception of histone H4K16. Although the functions
of hMSL and hNSL complexes in human cells are not very
clear, both complexes can acetylate histone H4 at lysine
16, suggesting the importance of acetylation of H4K16 in
cells. Except for acetylation of H4K16, NSL complex was
found to be able to acetylate the tumor suppressor protein
p53, and this acetylation is able to affect the behavior of
p53 in response to DNA damage [11]. It has been reported
that depletion of hMOF in human cells leads to genomic
instability, spontaneous chromosomal aberrations, cell cycle
defects, reduced transcription of certain genes, and defect-
ive DNA damage repair and early embryonic lethality [4-7].
This suggests a critical role for hMOF in fundamental pro-
cesses such as gene transcription, cell proliferation, differ-
entiation and DNA repair response. It is worth mentioning
that depletion of hMOF also leads to global reduction of
histone H4K16 acetylation in human cells [8,12]. However,
recent studies suggest that the global modification status of
H4K16Ac is also affected by Gcn-5-containing HAT and
SIRT-LSD1 HDAC complexes [13,14], indicating hMOF
might not be the only HAT fulfilling acetylation of H4K16
in cells. Although the role of histone H4K16 acetylation in
transcription regulation is not completely understood, loss
of H4K16 acetylation has been found in certain cancers.
Pfister et al. [15] found that frequent downregulation of
hMOF in large series of primary breast carcinomas and
medulloblastomas and hMOF protein expression tightly
correlated with acetylation of H4K16 in both cancers. In
addition, analysis of the tissue microarray slides revealed
low or absent histone H4K16 acetylation in majority of
breast cancer tissues [16].
Renal cell carcinoma (RCC) is one of the most com-
mon genitourinary malignancies, accounting for about
3% of all cancers worldwide [17]. With the improved im-
aging diagnostic technology, more RCC cases have been
diagnosed at an early stage. However, there is a consider-
able number of RCC patients at the time of diagnosis
has been transferred [18]. Research efforts have found
various biomarkers of diagnostic and prognostic of RCC
such as hypoxia-induced factor 1alpha (HIF1α), vascular
endothelial growth factor (VEGF), and carbonic anhy-
drase IX (CA9), but they are not specific and sensitive
enough to accurately predict the survival of RCC
patients [19-21]. Recent studies indicate that epigenetic
alterations play an important role in carcinogenesis, and
global histone modifications as predictors of cancer re-
currence in various tumor entities has begun to study.
Patients with RCC have been found that total acetylation
levels of histone H3 were inversely correlated with pT-
stage, distant metastasis, Fuhrman grading and RCC pro-
gression, whereas total histone H4Ac deacetylation was
correlated with pT-stage and grading [22]. All the above
observations strongly suggest that histone modificationsmight be involved in the development and progression of
RCC. However, it is not clear which particular enzyme or
specific modified lysine residue is responsible for tumori-
genesis in RCC. This study aims to assess hMOF expres-
sion and its corresponding acetylation of histone H4K16
in the RCC via qRT-PCR, western blotting and immuno-
histochemistry. Simultaneously, we also investigated the
correlation between the expression of hMOF and CA9.
Materials and methods
Materials
Anti-H4K16 (Cat# H9164) polyclonal antibody was pur-
chased from Sigma. Anti-MYST1 (Cat# A300-992A) was
obtained from Bethyl Laboratories. Anti-CA9 (Cat#
sc-25599) was from Santa Cruz Biotechnology. Anti-
GAPDH and anti-hMOF rabbit polyclonal antibodies
were raised against bacterially expressed proteins (Jilin
University).
Tissue collection
Human paired clinical RCC tissues and matched adja-
cent tissues were collected from patients with primary
RCC between March 2011 and May 2012, who under-
went kidney tumor radical surgery at the First Hospital
of Jilin University. The study was approved by the Ethics
Committee of the First Hospital of Jilin University and
all patients gave informed consent. All removed tissues
during the surgery were frozen immediately in liquid ni-
trogen and then stored at −80°C. Patient medical records
including tumor staging, pathological diagnosis, and sur-
gical records were reviewed. The pathologic diagnosis of
the resected tumors was based on the American Joint
Committee on Cancer [23]. All patients did not receive
chemotherapy or radiotherapy before surgery.
Cell culture and maintenance
Human embryonic kidney cell line HEK293T, human
clear cell renal cell carcinoma (ccRCC) cell lines 786–0
(TCHu3) and MN/CA9 positive human renal cell car-
cinoma cell line OS-RC-2 (TCHu40) were obtained from
Cell Resource Center of Shanghai Institute of Life
Science, Chinese Academy of Science. Cells were cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM,
Sigma) with 5% glucose and 10% fetal bovine serum,
100 U/mL penicillin, 100 mg/mL streptomycin in 10 cm
dishes at 37°C in a humidified atmosphere of 5% CO2.
Cultured cells were harvested from 1 well of 6-well
plate and lysed using ice-cold RIPA lysis buffer (50 mM
Tris HCl (pH7.4), 150 mM NaCl, 1% Nonidet P-40,
0.25% Na-deoxycholate, 1 mM EDTA and protease in-
hibitor cocktail). Following centrifugation at 12,000 × g
for 15 min at 4°C, total proteins in resulting supernatant
was quantified using the Bradford assay following the
manufacturer’s instruction (BioRad).
Figure 1 hMOF is downregulated in human ccRCC. A. Clinical informations of four newly diagnosed patients with ccRCC. B. hMOF mRNA
levels are dropped down in 4 random cases of ccRCC tissues. Total RNA from tissue was isolated using trizol. mRNA levels of hMOF, CA9, VEGF
and HIF1α in paired human clinical ccRCC and adjacent kidney tissue was analyzed by RT-PCR (upper panel). mRNA levels were quantified by
densitometry using Quantity One Basic software (Bio- Rad) (lower panel). C. Total hMOF protein expression and the acetylation of histone H4K16
levels are decreased in selected ccRCC tumor tissue. Aliquots of whole cell extracts from four selected ccRCC tumor samples and its
corresponding adjacent tissues were subjected to SDS-PAGE in 12% gels, and proteins were detected by western blotting with indicated
antibodies (upper panel). Western blot images were quantified using Quantity One software (Bio-Rad) (lower panel). The significant difference is
expressed as *p<0.05, **p<0.01, ***p<0.001. D. An example of immunostaining for hMOF and H4K16Ac in ccRCC. hMOF expression status in
adjacent renal tissue (a) and in ccRCC (b) were visualized by immunohistochemical staning with anti-MYST1 antibody. Acetylation levels of
modified histone H4K16 was immunostained by acetylation-specific antibody in adjacent renal tissue (c) and in ccRCC (d).
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Aliquot of whole cell extract from cultured cells was mixed
with 4xSDS sample buffer (0.25 M Tris–HCl pH 6.8, 8%
SDS, 30% Glycerol, 0.02% Bromophenol Blue containing
10% BME). Denatured proteins were separated by SDS
polyacrylamide gel (SDS-PAGE) and specific proteins were
analyzed by western blotting. 200 mg of kidney tissue sam-
ples were homogenized with liquid nitrogen and solubi-
lized in 200 μl cold PBS containing 1.0% Nonidet P-40,
0.5% Na- deoxycholate, 0.1% SDS, 0.05 mM PMSF and
protease inhibitor cocktail. The homogenate was swirled
and kept on ice for 30 minutes. Whole cell extracts were
prepared by sonication (SCIENTZ-IID, China) for 10 sec-
onds with 50% duty cycle and centrifugation at 12,000 rpm
for 15 min. Spectrophotometer used to measure protein
concentrations in a solution using a Bradford assay kit.
Equal total amounts of denatured proteins were separated
by SDS-PAGE. Specific proteins were detected by im-
munoblotting using hMOF, H4K16Ac, CA9 and GAPDH
polyclonal antibodies. Immunoblotted proteins were vi-
sualized using the chemiluminescent detection system
(PierceTechnology).Reverse transcription PCR (RT-PCR)
Cells were harvested from 1 well of a 6-well plate and total
RNA was isolated using TRIzolW LS Reagent (Invitrogen).
Total RNA from kidney tissues (normal/adjacent or
tumor) were also isolated using TRIzolW LS Reagent. 1 μ g
of RNA from each sample was used as a template to pro-
duce cDNA with PrimeScript 1st Strand cDNA Synthesis
Kit (TAKARA). hMOF, CA9 and GAPDH mRNA levels
were analyzed by Polymerase chain reaction (PCR) with
C1000™ Thermal Cycler (BIO-RAD) and quantitative real
time PCR with Real Time PCR Detector Chromo 4 (BIO-
RAD). All PCR reactions were finished under following
program: initial denaturation step was 95°C for 3 min, fol-
lowed by 35 cycles of denaturation at 95°C for 30 seconds,
annealing at 60°C for 30 seconds and extension at 72°C
for 30 seconds. The primer sets used for PCR were as
follows: GAPDH, 50-ATCACTGCCACCCAGAAGAC-30
(forward) and 50-ATGAGGTCCACCACCCTGTT-30 (re-
verse), yielding a 460 bp product; CA9, 50–GCAGGAG
GATTCCCCCTTG-3 (Forward) and 50-GGAGCCTC
AACAGTAGGTAGAT-30 (Reverse), yielding a 185 bp
product; hMOF, 50-GGCTGGACGAGTGGGTAGACAA-
Figure 2 Downregulation of hMOF is accompanied by increased CA9 in ccRCC. A-B. Relative mRNA expression levels of hMOF and CA9 in
ccRCC. Total RNA was isolated from sixteen paired clinical ccRCC and adjacent kidney tissues. Relative mRNA expression levels of hMOF and CA9
were analized by quantitative RT-PCR. Error bars represent the standard error of the mean of 3 independent experiments. Student’s t-test was
performed to compare the difference between ccRCC and normal tissues. C. Expression patterns of hMOF and CA9 mRNAs in ccRCC and its
corresponding adjacent kidney tissues. Expression is displayed as a ratio of expression of hMOF or CA9 gene in ccRCC versus matched normal
tissues. Each bar is the log2 value of the ratio of hMOF or CA9 expression levels between ccRCC and matched normal tissues from the same
patients. Bar value >1 represents >2-fold increased, whereas bar value <−1, represents >2-fold decreased. D. Protein expression levels of hMOF
and its H4K16Ac status in ccRCC. Aliquots of whole cell extracts from sixteen selected ccRCC tumor samples and its corresponding adjacent
tissues were analyzed by western blotting. The blots were then scanned and quantified with Quantity One software. The significant difference is
expressed as *p<0.05, **p<0.01.
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(reverse), yielding a 227 bp product.Immunohistochemical staining
Formalin-fixed and paraffin-embedded clear cell renal car-
cinoma tissue blocks were from the The First Clinical
Hospital of Jilin University. Tissue blocks were sectioned
and deparaffinized in xylene and rehydrated through a
graded ethanol series. Tissue slides were then subjected to
antigen retrieval by boiling in 0.01 M sodium citrate buffer
(pH 6) in a microwave oven for 10 min. Endogenous per-
oxidase was blocked by incubation for 10 min in 3%
hydrogen peroxide in methanol. Finally, the reactions were
detected using the DAB detection kit (Dako). Anti-
MYST1 and acetylated H4K16 polyclonal antibodies were
used at a 1:500 dilution. MYST1 protein expression status
and the histone H4K16 acetylation levels were estimated
in a four-step scale (none, weak, moderate, strong). The
determination criteria are shown below: score 0 = none,
no staining or nuclear staining <10% of tumor cells; score
1 = weak, partial or weak complete nuclear staining >10%
of tumor cells; score 2 = moderate complete nuclear stain-
ing >10% of tumor cells; score 3 = strong and complete
nuclear staining in >10% of tumor cells [24].Transient transfection
Human embryonic kidney (HEK) 293T cells, renal cell
carcinomas 786–0 and OS-RC-2 cells were cultured in 6
well tissue culture plates (~2 × 105 cells/well) in DMEM
containing 10% fetal bovine serum and antibiotics. The
cells were transiently transfected with 0.25~2 μg of
hMOF cDNAs using polyethylenimine (PEI). At 48 hrs
post-transfection, cells were harvested and lysed for
immunoblot and RT-PCR analysis.
Statistical analysis
The expression difference of genes and proteins between
ccRCC and normal tissues were statistically analyzed.
Statistical analysis was completed with SPSS 17.0 (SPSS,
Inc., Chicago IL). Statistical comparisons were analyzed
using the student’s t-test. Values of P < 0.05 were consid-
ered to be statistically significant.
Results
Downregulation of hMOF mRNA in primary renal cell
carcinoma tissues
In order to know whether the hMOF is involved in the
pathogenesis of primary RCC or not, we first examined
the mRNA levels of hMOF and other hypoxia signature
genes including CA9, VEGF and HIF1α in 4 random
Figure 3 hMOF is downregulated in different pathological diagnosis of human kidney cancer. A. Relative mRNA expression levels of
hMOF in different type of kidney cancer. Total RNA was isolated from four paired pathological diagnosed ccRCC, chRCC, paRCC, unclassified RCC,
respectively and matched normal/adjacent kidney tissues. Relative mRNA expression levels of hMOF and CA9 were analyzed by qRT-PCR. Error
bars represent the standard error of the mean of 3 independent experiments. B. Log2 ratio of hMOF and CA9 mRNA expression in four different
types of human kidney cancer. Ratio of mRNA expression is displayed as a ratio of expression of hMOF or CA9 gene in ccRCC versus matched
normal tissues. C. Analysis of werstern blotting. Equivalent total protein amount of whole cell extracts from four different pathological diagnosed
kidney cancers (ccRCC, chRCC, paRCC and unRCC) and its corresponding normal/adjacent tissues were subjected to SDS-PAGE in 12% gels, and
proteins were detected by western blotting with indicated antibodies. D. Summarization of hMOF and CA9 expression in RCC. Total cases of
ccRCC (21) include four initial selected ccRCC (data not shown), sixteen additional ccRCC and one case used in comparing experiment.
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transcription PCR (RT-PCR) and quantitative real-time
PCR (qPCR). As shown in Figure 1B, the gene expres-
sion levels of hMOF were markedly decreased in all
ccRCC tissues compared to matched normal tissues
(p<0.001). In contrast, CA9 expression levels were sig-
nificantly increased in all ccRCC tissues (p<0.01). How-
ever, no significant difference was observed in VEGF and
HIF1α expression. Additional 16 paired clinical ccRCC
and matched normal tissues were used to further valid-
ate the frequent downregulation of hMOF mRNA ex-
pression in primary ccRCC. Analysis of performed
mRNA expression of 16 samples revealed significant
(>2-fold decreased) downregulation of hMOF mRNA in
87.5% (14/16) of patients (Figure 2A and C), whereas
12.5% (2/16) of patients showed significant (>2-fold
increased) upregulation of hMOF (Figure 2A and C).
However, less relationship between hMOF expression
and tumor size, stage and grading was detected in our
limited number of cases (data not shown). To examine
the gene expression status of hMOF in other types ofRCC, four kidney cancer patients with pathologically
daignosed ccRCC, chRCC (chromophobe RCC), paRCC
(papillary RCC) and unRCC (unclassified RCC), respect-
ively, were selected. Analysis of qRT-PCR results showed
that the gene expression of hMOF significantly downre-
gulated in all types of RCC (>2-fold) (Figure 3A and B).
Reduction of hMOF protein in human primary renal cell
carcinoma tissues
The results of RT-PCR analysis clearly show frequent
downregulation of hMOF gene expression in RCC. To
determine whether the reduction of hMOF mRNA ex-
pression resulted in decreasing of hMOF protein levels,
western blotting and immunohistochemical staining
approaches were used. As shown in Figure 1C, aliquots
of whole cell extract from four paired initially selected
ccRCC and matched normal tissues were analyzed by
western blotting with indicated antibodies. Similar to
our expected results, significant reduction of hMOF pro-
tein in ccRCC compared to those of matched normal
tissues were detected (p<0.05). Simultaneously, the
Figure 4 Non-correlation between hMOF and CA9 is found in renal cell carcinoma cells. A. hMOF protein expression was correlated with
acetylation of H4K16 in RCC cell 786–0 and OSRC-2. 293T, 786–0 or OSRC-2 cells were cultured in 6-well tissue culture plates (~2x105 cells/well) in
DMEM medium containing 10% fetal bovine serum. Whole cell extracts were subjected to immunoblotting using indicated antibodies (right
panel). 293T, 786–0 or OSRC-2 cells from 1 well of a 6 well plate were lysed and total RNA was isolated using Trizol. hMOF and CA9 gene
expressions were measured by RT-PCR (left panel) and qRT-PCR (B). C. Effect of hMOF on CA9 mRNA expression levels in RCC cells. RCC 786–0
cells were cultured in 6-well tissue culture plates (~2x105 cells/well) in DMEM medium containing 10% fetal bovine serum. The cells were
transfected with 0.25, 0.5, 1 and 2 μg of hMOF cDNAs. 48 hours after transfection, cells were lysed and total RNA was isolated using Trizol.
Indicated gene expressions were analyzed by qRT-PCR. D. Effect of hMOF on CA9 protein expression in RCC cells. RCC 786–0 cells were
transfected with 0.25, 0.5, 1 and 2 μg of hMOF cDNAs. 48 hours after transfection, cells were harvested and lysed in RIPA buffer. Aliquots of whole
cell extracts were subjected to 12% SDS-PAGE, and specific proteins were detected by indicated antibodies.
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cantly reduced or lost (p<0.05). To further confirm these
results, we performed immunohistochemical staining for
hMOF and histone H4K16 acetylation in the formalin
fixed paraffin embedded tissue sections of same four
selected ccRCC patients. The results revealed that both
the hMOF protein levels and the histone H4K16 acetyl-
ation status were markedly reduced (score 1 to 2 for
hMOF staining, and score 0–1 for H4K16Ac staining) in
all ccRCC tissues compared to adjacent tissues. For ex-
ample, the results of immunohistochemical staining for
hMOF and H4K16Ac are presented in Figure 1D. Weak
staining of hMOF and no staining of H4K16Ac in the
ccRCC paraffin embedded tissue sections were detected.
In the additional 16 paired clinical ccRCC and matched
normal tissues, hMOF protein expression and H4K16Ac
status were detected by western blotting. The quantified
protein levels (Quantity One software) were analyzed by
t-test. As shown in Figure 2D, hMOF protein expression
levels were significantly reduced in ccRCC tissues
(p<0.01), and the expression of hMOF was tightly corre-
lated with H4K16 acetylation (p<0.05). Furthermore, in
the four different pathologically diagnosed ccRCC,
chRCC, paRCC and unRCC, hMOF protein expression
was significantly decreased in ccRCC, chRCC andunclassified RCC, whereas less changes were detected in
paRCC (Figure 3C).
Elevation of CA9 gene expression is accompanied by
frequent reduction of hMOF mRNA in ccRCC
CA9 is not expressed in healthy renal tissue but is
expressed in most ccRCC through HIF1α accumulation
driven by hypoxia [25]. In our study, the gene expression
of CA9 was significantly increased (>2-fold) in 100% of
ccRCC patients (21/21; Figure 3D) including four initial
selected ccRCC, sixteen additional ccRCC (Figure 2B) and
one case (Figure 3A and B) used in comparing experi-
ment. Among these cases, reduction of hMOF mRNA ex-
pression was detected in 90.5% of cases (19/21). There
were only 2 cases presenting elevation of hMOF mRNA
expression in ccRCC (Figure 2A and C). However, no ele-
vation of CA9 gene expression was detected in different
pathologically diagnosed RCC including chRCC, paRCC
and unRCC, although the mRNA levels of hMOF were
significantly decreased in those RCC (Figure 3B).
Non-correlation between hMOF and CA9 is found in renal
cell carcinoma cells
To extend these observations and to know whether
there is a correlation regulatory relationship between
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using RCC cell 786–0 and OS-RC-2 as model. We first
examined both the protein levels and mRNA expression
levels of the hMOF and CA9 in 293T, 786–0 and OS-
RC-2 cells. The results as shown in Figure 4A indicate
the opposing gene expression patterns between hMOF
and CA9 were observed. The expression of hMOF was
reduced in both 786–0 and OS-RC-2 cells compared to
293T cells, and the log2 ratio changes are −0.84 and −1.9,
respectively. Western blotting analysis revealed that the
hMOF proteins were markedly decreased in both renal
cell carcinoma cells. In addition, the reduction of hMOF
proteins resulted in loss of the acetylation of histone
H4K16 in RCC cells. In contrast with hMOF, the gene ex-
pression of CA9 was increased in both 786–0 (log2=6.2)
and OS-RC-2 cells (log2=12.3) compared to 293T cells.
To determine whether the CA9 gene expression was regu-
lated by hMOF, renal cell carcinoma 786–0 cells were
transiently transfected with 0.25 to 2 μg of hMOF cDNAs.
The results are shown in Figure 4C and D, both the gene
and protein expression levels of hMOF were dose-
dependently increased. However, neither the gene nor pro-
tein expression of CA9 levels were affected by transient
transfection RCC 786–0 cells with hMOF cDNAs.
Discussion
The HAT hMOF belongs to the MYST (Moz-Ybf2/Sas3-
Sas2-Tip60) family, and is believed to be responsible for
histone H4 acetylation at lysine 16 in both Drosophila
and human cells [7,8,12]. Abnormal expression of the
hMOF and its corresponding modification of H4K16
have been found in certain primary cancer tissues. The
expression behavior of hMOF in different primary can-
cers was observed to be different. Frequent downregula-
tion of hMOF expression was found in primary breast
cancer and medulloblastoma [15]. On the contrary,
hMOF was overexpressed in non-small cell lung carcin-
oma tissues [26]. Regardless of what type of situation,
hMOF protein expression tightly correlated with acetyl-
ation of histone H4K16. In this study, we investigated
the expression of histone acetyltransferase hMOF and its
corresponding H4K16 acetylation in a series of primary
kidney tumor tissues by qRT-PCR, western blotting, and
immunohistochemistry. The results revealed that either
hMOF mRNA expression or hMOF protein expression
was frequently downregulated in human RCC (19/21
cases; >90%), and hMOF protein expression was corre-
lated with acetylation of histone H4K16 in parallel. In
addition, low protein expression levels of hMOF and loss
of histone H4K16 acetylation were detected in renal car-
cinoma cells 786–0 and OS-RC-2 compared to human
embryonic kidney cell HEK293T. Together this, HAT
hMOF might have an important role in primary renal
cell carcinoma tumorigenesis.CA9 is a transmembrane, zinc-containing metalloen-
zyme that catalyzes reversible reactions of the bicarbonate
buffer system to regulate pH in hypoxic conditions [27].
Overexpression of CA9 has been shown in a wide variety
of malignant cell lines and tumors [28-30]. It is worth
mentioning that CA9 has been well described as a diag-
nostic marker for clear cell renal carcinoma (ccRCC), es-
pecially by showing high expression in metastastic ccRCC
(mccRCC) [31,32]. Therefore, the inhibitor or regulatory
proteins of hypoxic tumor-associated CA9 possesses the
potential therapeutic possibility for those tumors in which
CA9 is involved in perturbing the extra- or intra- tumoral
acidification process. In our experiments, although the ex-
pression of VEGF and HIF1α which are hypoxia signature
genes were not observed significant difference between
ccRCC and normal tissues, overexpression of CA9 was
observed in 100% of ccRCC cases and in both renal car-
cinoma cell lines. Interestingly, in four different diagnostic
RCCs, downregulation of hMOF was detected in all types
of RCCs, but the overexpression of CA9 was only pre-
sented in ccRCC, suggesting that hMOF might be a new
common diagnostic marker for human different diagnostic
RCC. Although frequent downregulation of hMOF and
overexpression of CA9 were detected in both RCC clinical
tissues and RCC cell lines, non-correlation between
hMOF and CA9 was found in RCC 786–0 cells, suggesting
hMOF and its corresponding modifications might be a
new CA9-independent RCC diagnosis biomarker. Al-
though large series of clinical cases and analyses of overall
survival need to be investigated, the molecular mechanism
linking loss of hMOF expression to renal cell carcinoma,
especially mechanism of hMOF on renal cell carcinomas,
will be an exciting avenue for further research.
Conclusion
In conclusion, hMOF as an acetyltransferase of H4K16
might be involved in the pathogenesis of renal cell car-
cinoma, and this epigenetic change might be a new
CA9-independent RCC diagnostic marker. In addition,
our results suggest that a novel molecular mechanism of
hMOF might serve as a lead to new therapeutics target
in human renal cell carcinoma.
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